Company research
Transcode Therapeutics, Inc.
CIK 1829635Updated Sep 24, 2026
SecurityRNAZ · NASDAQ · equity
RNAZ price & chart
Loading TradingView…
NASDAQ:RNAZ on TradingView ↗About the company
TransCode is a clinical-stage company pioneering immuno-oncology and RNA therapeutics for treatment of high risk and advanced cancers We possess a diversified pipeline of therapeutic candidates, including two clinical stage assets, TTX-MC138, an antisense inhibitor of an oncogenic microRNA and Seviprotimut-L, a cancer vaccine. We also possess an oncolytic immunotherapy platform and three TTX-based pre-clinical stage assets.
In the news
TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split News provided by TransCode Therapeutics, Inc. May 05, 2025, 17:07 ET Share this article Share to X Share this article Share to X BOSTON , May 5, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ ) ("TransC ↗
Seeking Alpha
TransCode Therapeutics, Inc. (RNAZ) Discusses Advancing Multi-Platform Oncology Pipeline Targeting Metastatic Cancer Transcript ↗
TransCode Therapeutics CFO retires ↗
TransCode Therapeutics, Inc. (RNAZ) Discusses Strategic, Scientific, and Clinical Updates With Focus on TTX-MC138 Phase 2a Trial in Colorectal Cancer Prepared Remarks Transcript ↗
Recent filings
3 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
10-Q filing
Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Items 3.03, 5.03, 9.01
SCHEDULE 13G filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 162,398,689Source | 7,294,499Source | 5,169,701Source | 7,587,986Source |
| Property, Plant and Equipment, NetUSD | 370,681Source | 51,574Source | 120,707Source | 208,581Source |
| GoodwillUSD | 25,744,143Source | — | — | — |
| Intangible Assets, Net (Excluding Goodwill)USD | 114,300,000Source | — | — | — |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 17,813,521Source | 5,811,064Source | 2,767,598Source | 4,968,418Source |
| Assets, CurrentUSD | 21,983,865Source | 7,093,338Source | 4,455,444Source | 7,379,405Source |
| Prepaid Expense and Other Assets, CurrentUSD | 919,440Source | 1,282,274Source | 1,687,846Source | 2,050,758Source |
| Operating Lease, Right-of-Use AssetUSD | — | 37,731Source | 481,694Source | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 10,518,687Source | 9,313,233Source | 3,528,887Source | 4,347,290Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 92Source | 103Source | 63Source | 1,298Source |
| Additional Paid in CapitalUSD | 108,198,366Source | 61,183,079Source | 48,057,095Source | 31,109,647Source |
| Retained Earnings (Accumulated Deficit)USD | -97,862,992Source | -63,201,916Source | -46,416,344Source | -27,870,249Source |
| Stockholders' Equity Attributable to ParentUSD | 10,335,466Source | -2,018,734Source | 1,640,814Source | 3,240,696Source |
| Liabilities and EquityUSD | 162,398,689Source | 7,294,499Source | 5,169,701Source | 7,587,986Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 3,494,220Source | 2,771,836Source | 3,490,596Source | 4,347,290Source |
| Operating Lease, Liability, CurrentUSD | — | 38,291Source | 412,280Source | — |
| Operating Lease, Liability, NoncurrentUSD | — | — | 38,291Source | — |
| Deferred Income Tax Liabilities, NetUSD | 226,068Source | — | — | — |
| Additional Financial Items | ||||
| Deferred Tax Liabilities, NetUSD | 226,068Source | — | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -34,661,076Source | -16,754,971Source | -18,546,095Source | -17,564,968Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 76,446Source | 90,894Source | 123,483Source | 98,606Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 485,428Source | 1,699,999Source | 1,036,889Source | 395,329Source |
| Deferred Income Tax Expense (Benefit)USD | 226,068Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -19,516,229Source | -13,335,947Source | -18,074,535Source | -15,762,512Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -4,436Source | -21,761Source | -35,609Source | -100,919Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 6,660Source | 21,761Source | 35,609Source | 100,919Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 31,523,122Source | 16,401,174Source | 15,909,324Source | 5,989Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 12,002,457Source | 3,043,466Source | -2,200,820Source | -15,857,442Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 17,813,521Source | 5,811,064Source | 2,767,598Source | 4,968,418Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 6,501Source | 16,629Source | 32,861Source | 37,115Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | 395,329Source |
| DepreciationUSD | 76,446Source | 90,894Source | 123,483Source | 98,606Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -112,065Source | -57,062Source | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | 500Source | — | — |
| General and Administrative ExpenseUSD | 5,771,063Source | 5,954,339Source | 7,154,986Source | 8,433,448Source |
| GoodwillUSD | 25,744,143Source | — | — | — |
| Goodwill, Impairment LossUSD | 0Source | — | — | — |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | 0Source | — | — | — |
| Income Tax Expense (Benefit)USD | 226,069Source | 0Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | 6,616Source | — | — | — |
| Investment Income, InterestUSD | 79,198Source | 684Source | 5,285Source | 20,410Source |
| Net Income (Loss) Attributable to ParentUSD | -34,661,076Source | -16,754,971Source | -18,546,095Source | -17,564,968Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -36,271,287Source | -16,785,572Source | — | — |
| Noncash Merger Related CostsUSD | 6,836,992Source | — | — | — |
| Nonoperating Income (Expense)USD | -6,454,937Source | -1,094,274Source | 872,421Source | 1,100,846Source |
| Operating ExpensesUSD | 27,980,071Source | 15,660,697Source | 19,418,516Source | 18,665,814Source |
| Proceeds from Issuance of Common StockUSD | 8,854,798Source | 16,401,174Source | 15,909,324Source | 1,300,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | 5,989Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -27,980,071Source | -15,660,697Source | -19,418,516Source | -18,665,814Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -34,435,008Source | — | — | — |
| Income Tax Expense (Benefit)USD | 226,069Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -34,661,076Source | -16,754,971Source | -18,546,095Source | -17,564,968Source |
| Earnings Per Share, BasicUSD per share | -52.59Source | -47.14Source | -103.61Source | -1.35Source |
| Earnings Per Share, DilutedUSD per share | -52.59Source | -47.14Source | -103.61Source | -1.35Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 689,713Source | 356,115Source | 179,006Source | 12,977,234Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 689,713Source | 356,115Source | 179,006Source | 12,977,234Source |
| Interest Expense (non-operating)USD | 6,616Source | — | — | — |
| Additional Financial Items | ||||
| Business Combination, Acquisition Related CostsUSD | 8,787,160Source | — | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -112,065Source | -57,062Source | — | — |
| General and Administrative ExpenseUSD | 5,771,063Source | 5,954,339Source | 7,154,986Source | 8,433,448Source |
| Goodwill, Impairment LossUSD | 0Source | — | — | — |
| Interest ExpenseUSD | — | 26,813Source | 55,899Source | — |
| Investment Income, InterestUSD | 79,198Source | 684Source | 5,285Source | 20,410Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -36,271,287Source | -16,785,572Source | — | — |
| Nonoperating Income (Expense)USD | -6,454,937Source | -1,094,274Source | 872,421Source | 1,100,846Source |
| Operating ExpensesUSD | 27,980,071Source | 15,660,697Source | 19,418,516Source | 18,665,814Source |
| Research and Development ExpenseUSD | 13,421,848Source | 9,706,358Source | 12,263,530Source | 10,232,366Source |
Offerings
Registration 333-295481
Filing attachments
tm2618153d1_ex99-1.htm · 8-K · 2026-06-18
EX-99.1 2 tm2618153d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Three Platforms, One Mission: Transforming Advanced Cancer Care NASDAQ: RNAZ Company Forward Looking Statement 2 Before you invest in the securities of TransCode Therapeutics, Inc. (“TransCode” or the “Company”), you should read TransCode’s filings with the U.S. Securities and Exchange Commission (“SEC”) for more complete information about the Company. You can obtain these documents for free by visiting EDGAR on the…
Read attachment ↗tm2616719d1_ex99-1.htm · 8-K · 2026-06-03
EX-99.1 2 tm2616719d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer TransCode reports no dose-limiting toxicities, durable disease stabilization in metastatic patients; advances to Phase 2 development in ctDNA-positive cancers using next-generation RNA therapeutics. BOSTON, June 3, 2026 - TransCode Therapeutics, Inc. (NASDAQ: RNAZ) a clinical stage company…
Read attachment ↗tm2611272d1_ex4-1.htm · 8-K · 2026-04-07
EX-4.1 2 tm2611272d1_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 NEITHER THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THESE SECURITIES HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ SECURITIES ACT ”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER TH…
Read attachment ↗tm2611272d1_ex4-2.htm · 8-K · 2026-04-07
EX-4.2 3 tm2611272d1_ex4-2.htm EXHIBIT 4.2 Exhibit 4.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) dated as of April 6, 2026 is made by and between YA II PN, LTD., a Cayman Islands exempt limited company (the “Investor”), and TRANSCODE THERAPEUTICS, INC., a company incorporated under the laws of the State of Delaware (the “Company”). The Investor and the Company may be referred to herein individually as a “Party” and collectively as the “Parties.” W…
Read attachment ↗tm2611272d1_ex99-1.htm · 8-K · 2026-04-07
EX-99.1 5 tm2611272d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company’s Runway into Late 2027/Early 2028 BOSTON, April 7, 2026 - TransCode Therapeutics, Inc. (NASDAQ: RNAZ, the “Company”), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced that it has entered into an agreement with an institutional healthcare investor fo…
Read attachment ↗